Brolucizumab 6 mg
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Proliferative Diabetic Retinopathy
Conditions
Proliferative Diabetic Retinopathy
Trial Timeline
Nov 19, 2020 → Aug 19, 2024
NCT ID
NCT04278417About Brolucizumab 6 mg
Brolucizumab 6 mg is a phase 3 stage product being developed by Novartis for Proliferative Diabetic Retinopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04278417. Target conditions include Proliferative Diabetic Retinopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04278417 | Phase 3 | Completed |
Competing Products
20 competing products in Proliferative Diabetic Retinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Navitoclax + Ruxolitinib + Celecoxib | AbbVie | Phase 1 | 33 |
| Epcoritamab | AbbVie | Phase 1 | 33 |
| CANAKINUMAB (ILARIS®) | Novartis | Phase 1 | 33 |
| Lucentis | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Octreotide, 30 mg i.m. LAR formulation | Novartis | Phase 3 | 77 |
| Ranibizumab 0.5 mg | Novartis | Phase 2 | 52 |
| AUY922 | Novartis | Phase 2 | 52 |
| Lucentis | Roche | Pre-clinical | 23 |
| Macugen (pegaptanib) + Macugen (Pegaptanib) | Pfizer | Pre-clinical | 22 |
| Macugen ® (pegaptanib sodium) | Pfizer | Approved | 84 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 51 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 2 | 51 |
| VAC85135 + Ipilimumab | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg | Bristol Myers Squibb | Phase 1 | 32 |
| Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 51 |
| 2-mg Intravitreous Aflibercept Injection | Regeneron Pharmaceuticals | Phase 2/3 | 64 |